Response to different therapeutic approaches in Wilson disease A long term follow up study
Texto completo
Documento similar
This study sought to analyze tumor CXCL5 gene expression in six patients with different efficacy of BVZ-containing CT in terms of the tumor response to treatment..
One trial evaluated maintenance therapy with certolizumab pegol versus placebo after response to induction with certolizumab, finding that 36% of patients in the treatment
Fig 4. Comparison of EULAR and HUPI response criteria from baseline at different weeks of patients from ACT-RAY. A) Percentage of patients getting none, moderate or good response
In the preparation of this report, the Venice Commission has relied on the comments of its rapporteurs; its recently adopted Report on Respect for Democracy, Human Rights and the Rule
Conclusions: Our experience suggests that 1000 mg rituximab single in- fusion on demand is a reasonable schedule for long-term treatment of those patients with good response after
Prospective observational study evaluating the association of 124 polymorphisms with the response to adalimumab or infliximab (PASI75) in patients with moderate-to-severe
Circulating interleukin 6 and albumin, and infliximab levels are good predictors of recovering efficacy after dose escalation infliximab therapy in patients with loss of response
ACS Paragon Plus Environment.. 24 diagrams of the direct DNA sensor response to clinical samples; d) bar diagrams of the. response to clinical samples of a sensor prepared